ImmunoGeneTeqs was established in June 2019 as a Tokyo University of Science venture company with the aim of providing methods to control inflammation and immune intractable diseases based on better genetic analysis technology.

Our company provides contract services for T cell receptor (TCR) repertoireand single cell gene expression (scRNA-seq) analysis while introducing TAS-Seq technology developed by Tokyo University of Science, etc. We hope to contribute to society through the development of clinical test drugs, novel T cell therapies, vaccine therapies, and 1 cell information database. We hope to contribute to society through the development of clinical test drugs, novel T-cell therapies, vaccine therapies, and 1-cell information databases.